Equity Profile

NVO

Novo Nordisk A/S

Health CarePharmaceuticals$188.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novo Nordisk A/S is a leading global healthcare company specializing in pharmaceuticals, particularly in diabetes care and hormone replacement therapies. With a market cap of $202 billion, its innovations play a crucial role in addressing chronic health issues, making it a significant player in the health care sector.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely watch.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, vital for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, surpassing estimates by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Focus on expanding diabetes care products.
Commitment to innovation in hormone therapies.
Plans to enhance global market reach.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, hoping for strong performance in diabetes drug sales and overall profitability.

Bull Case

If Novo Nordisk continues to outperform in diabetes treatments and shows strong revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the specific sales figures for diabetes medications this quarter?

Sales performance in this segment is crucial as it directly impacts overall revenue and investor confidence.

How does management view the competitive landscape for diabetes treatments?

Understanding management's perspective on competition can provide insights into future growth potential and market strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the growth potential of Novo Nordisk's diabetes drug segment, given recent trends in chronic disease management.

Supporting Evidence

Recent sales trends indicate a stronger demand for diabetes medications than anticipated.

The options market is pricing in a larger move than historical averages suggest, indicating potential overreaction.

Management's previous commitments to innovation could lead to unexpected revenue boosts.

Key Risk

If diabetes drug sales exceed expectations significantly, it could challenge the current consensus on growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Novo Nordisk can maintain its growth trajectory in a competitive environment.

Bull Confirmed If

Strong diabetes drug sales growth exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in diabetes drug sales or lower-than-expected EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3.6%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious guidance, the stock may see muted movement, reflecting uncertainty.

Miss

A miss on earnings could lead to a decline of approximately 4.1%, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on diabetes medication sales figures.
2Management's outlook on competitive pressures.
3Any new product announcements or pipeline updates.
4Insights into global market expansion efforts.
5Comments on cost management and profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely watch.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, vital for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, surpassing estimates by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Focus on expanding diabetes care products.
Commitment to innovation in hormone therapies.
Plans to enhance global market reach.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, hoping for strong performance in diabetes drug sales and overall profitability.

Bull Case

If Novo Nordisk continues to outperform in diabetes treatments and shows strong revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the specific sales figures for diabetes medications this quarter?

Sales performance in this segment is crucial as it directly impacts overall revenue and investor confidence.

How does management view the competitive landscape for diabetes treatments?

Understanding management's perspective on competition can provide insights into future growth potential and market strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the growth potential of Novo Nordisk's diabetes drug segment, given recent trends in chronic disease management.

Supporting Evidence

Recent sales trends indicate a stronger demand for diabetes medications than anticipated.

The options market is pricing in a larger move than historical averages suggest, indicating potential overreaction.

Management's previous commitments to innovation could lead to unexpected revenue boosts.

Key Risk

If diabetes drug sales exceed expectations significantly, it could challenge the current consensus on growth.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Novo Nordisk can maintain its growth trajectory in a competitive environment.

Bull Confirmed If

Strong diabetes drug sales growth exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in diabetes drug sales or lower-than-expected EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3.6%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious guidance, the stock may see muted movement, reflecting uncertainty.

Miss

A miss on earnings could lead to a decline of approximately 4.1%, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on diabetes medication sales figures.
2Management's outlook on competitive pressures.
3Any new product announcements or pipeline updates.
4Insights into global market expansion efforts.
5Comments on cost management and profitability.